The bio tech stocks have on average risen by 188% this year and have a median upside potential of 150%.
Related Posts
Chevron beats earnings expectations, returns more than $7 billion to shareholders
Chevron’s stock is largely flat for the year, underperforming the S&P 500 energy sector which has gained more than 6%.
Nvidia passes Apple as world’s most valuable company
Nvidia shares have nearly tripled this year as demand continues to swell for the company’s graphics processing units.